Montana Expands 'Right to Try' Access to Non-Terminally Ill Patients
New legislation allows patients to access experimental drugs after Phase I trials, bypassing traditional FDA terminal-illness requirements.
Montana has fundamentally altered the landscape of medical access by expanding its "Right to Try" laws to include patients who are not terminally ill. The move allows individuals to seek experimental treatments provided the drugs have completed Phase I clinical trials, a significant departure from federal norms that typically reserve such access for those with life-threatening conditions.
Under the framework established by SB 535, the state has created a licensing system for "experimental treatment centers" and formed the Experimental Treatment Review Board (ETRB) to oversee applications. This regulatory shift is designed to create a domestic pathway for patients to access cutting-edge medicine without leaving the United States. For parents like Kris DeVault, whose son Brody suffers from creatine transporter deficiency, the law represents a critical opportunity to pursue treatments that could alter the trajectory of a child's life. DeVault has questioned why adults should be barred from making decisions regarding potential treatments for their children.
The Shift in Medical Regulation
Traditional Right to Try laws were designed as a last resort for the terminally ill, providing a legal bridge to FDA-experimental drugs when all other options were exhausted. Montana's new approach aims to transform the state into a hub for medical tourism and longevity treatments. By lowering the threshold for access, the state seeks to reduce the incentive for patients to travel to offshore clinics in jurisdictions like Honduras, where unproven therapies are often administered outside of U.S. oversight.
Industry and Ethical Friction
Despite the legal pathway, the transition from law to practice faces significant hurdles. Biotech companies, including Ceres Brain Therapeutics, have expressed hesitation about utilizing the Montana pathway, citing concerns over potential repercussions from the FDA. The tension highlights a conflict between state-level patient autonomy and federal regulatory authority.
Bioethicists have also raised alarms regarding the safety of the new mandate. Sharona Hoffman, a professor of law and bioethics at Case Western Reserve University, described the availability of drugs after only Phase I testing as "disturbing," warning that such a move could endanger patients. Because Phase I trials are primarily designed to test safety in small groups rather than efficacy, critics argue that vulnerable patients may be exposed to dangerous side effects without a proven benefit.
Future Outlook
As Montana begins to implement this framework, the medical community will be watching to see if biotech firms eventually yield to patient demand or if FDA pressure keeps the pipeline closed. The success of the ETRB in managing applications will likely determine whether the state becomes a viable alternative to international medical tourism or a cautionary tale regarding the premature deployment of experimental medicine.